产品中心您现在的位置:首页 > 产品展示 > > 天然免疫研究产品 > Anti-mPD-1-mIgG1e3 InvivoFit™

Anti-mPD-1-mIgG1e3 InvivoFit™

更新时间:2022-01-29

简要描述:

Anti-mPD-1-mIgG1e3 InvivoFit™ is a recombinant monoclonal antibody (mAb) featuring the variable region of the previously described anti-mPD-1 RMP1-14 mAb [1, 2]. The original RMP1-14 hybridoma was ob…

型号:厂商性质:代理商浏览量:146

Recombinant mouse mAb against murine PD-1 for in vivo use

Anti-mPD-1-mIgG1e3 InvivoFit™ is a recombinant monoclonal antibody (mAb) featuring the variable region of the previously described anti-mPD-1 RMP1-14 mAb [1, 2]. The original RMP1-14 hybridoma was obtained by immunizing rats with cells expressing murine programmed cell death 1 (mPD-1; also known as CD279). The use of xenogeneic sequences (i.e. rat origin) for mAbs renders them immunogenic upon injection in mice [3]. Moreover, special attention should apply to mAbs targeting the PD-1/PD-L1 axis, as repeated injections of xenogeneic anti-PD-1 or anti-PD-L1 in tumor-bearing mice were shown to induce fatal hypersensitivity reactions [4].  To overcome this issue, Anti-mPD-1-mIgG1e3 InvivoFit™ was generated by recombinant DNA technology so that it is ~65% murine. It contains the constant region of mouse IgG1 with a D265A point mutation (replacement of aspartic acid by alanine at position 265) resulting in the complete loss of cytolytic effector function [2, 5]. Anti-mPD-1-mIgG1e3 is provided in an InvivoFit grade, a high-quality standard specifically adapted to in vivo studies.

 

Key features of Anti-mPD-1-mIgG1e3 InvivoFit™:

  • Derives from the RMP1-14 clone, rat IgG2a,κ

  • Features mouse IgG1e3 isotype (constant region)

  • mIgG1e3 (IgG1 with a D265A point mutation) is effectorless

  • Blocks the murine PD-1 receptor without causing T cell depletion

  • Guaranteed sterile, endotoxin level < 1 EU/mg

  • Specifically designed for in vivo studies in mice

  • Low aggregation < 5%

  • Produced in animal-free facilities and defined media

Anti-mPD -1-mIgG1e3 InvivoFit™ is produced in Chinese hamster ovary (CHO) cells, purified by affinity chromatography with protein A, and its binding is validated by flow cytometry and ELISA.

 

References:

1. Ribas A. & Wolchock J.D., 2018. Cancer immunotherapy using checkpoint blockade. Science. 359:1350-55. 
2. Yamazaki T. et al.2005. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production. J Immunol. 175(3):1586-92.
3. Brüggemann M. et al., 1989. The immunogenicity of chimeric antibodies. J. Exp. Med. 170:2153-2157. 
4. Mall C. et al., 2016. Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer. Oncoimmunology. 5(2):e1075114.
5. Baudino L. et al., 2008. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J. Immunol. 181(9):6664-9.
 

Figures


Specifications

Specificity: Targets cells expressing murine PD-1

Formulation: Lyophilized from 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose

Clonality: Monoclonal antibody

Isotype: Murine IgG1e3 (D265A mutation; no effector function), kappa 

Source: CHO cells

Purity: Purified by affinity chromatography with protein A

Tested applications: Flow cytometry and ELISA

Quality control:

  • Binding confirmed by flow cytometry

  • The complete sequence of this antibody has been verified

  • < 5% aggregates (confirmed by size exclusion chromatography)

  • Guaranteed sterile and <1 EU/mg (determined by the LAL assay)


Contents

Anti-mPD-1-mIgG1e3 InvivoFit™ is provided sterile, endotoxin-free, azide-free and lyophilized.  

This product is available in three pack sizes:

  • mpd1-mab15-1: 1 mg

  • mpd1-mab15-10: 10 mg

  • mpd1-mab15-50: 50 mg (5 x 10 mg)

 

room temperature Product is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

stability Lyophilized product is stable for at least 1 year

Alert Avoid repeated freeze-thaw cycles.


Details

Programmed cell death 1 (PD-1; also known as CD279) is a type I transmembrane protein expressed at the cell surface of activated and exhausted conventional T cells. PD-1 is an inhibitory immune checkpoint that prevents T-cell overstimulation and host damage.
PD-1 interaction with its ligands PD-L1 (programmed cell death ligand 1) or PD-L2 induces inhibition of T-cell receptor signaling. Blockade of PD-1 with mAbs has allowed unprecedented remissions in patients with metastatic melanoma or non-small cell lung cancer. 


如需购买或咨询该产品技术问题,请联系Invivogen一级代理商--欣博盛生物

留言框

  • 产品:

  • 您的单位:

  • 您的姓名:

  • 联系电话:

  • 常用邮箱:

  • 省份:

  • 详细地址:

  • 补充说明:

  • 验证码:

    请输入计算结果(填写阿拉伯数字),如:三加四=7

上一篇:ATP

下一篇:Alhydrogel® adjuvant

返回列表>>
在线咨询
在线客服